Instil BioTIL
TIL
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
533% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 3
1.64% less ownership
Funds ownership: 81.86% [Q3] → 80.21% (-1.64%) [Q4]
20% less funds holding
Funds holding: 49 [Q3] → 39 (-10) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q3] → 3 (-2) [Q4]
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
72% less capital invested
Capital invested by funds: $358M [Q3] → $100M (-$258M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
206%
upside
Avg. target
$81
376%
upside
High target
$110
546%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 33% 1-year accuracy 59 / 181 met price target | 546%upside $110 | Buy Reiterated | 5 Mar 2025 |
Jefferies Kelly Shi 33% 1-year accuracy 3 / 9 met price target | 206%upside $52 | Buy Upgraded | 7 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025
Neutral
GlobeNewsWire
2 months ago
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
Positive
Benzinga
2 months ago
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.
Positive
Seeking Alpha
3 months ago
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM forecasted to reach $43.7 billion by 2026.
Positive
The Motley Fool
6 months ago
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.
Negative
Benzinga
6 months ago
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday.
Positive
Zacks Investment Research
6 months ago
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
Neutral
GlobeNewsWire
6 months ago
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC).
Positive
The Motley Fool
6 months ago
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda.
Positive
Seeking Alpha
6 months ago
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing.
Charts implemented using Lightweight Charts™